Processa Pharmaceuticals transitions Chief Development Officer to part-time role effective May 1, 2026

Processa Pharmaceuticals, Inc.

Dr. Sian Bigora moves from full-time executive to part-time employee, retains Chief Development and Regulatory Officer title.
She will no longer be an executive officer under Section 16 of the Exchange Act.
Existing employment agreement terminated; replaced by new part-time arrangement effective May 1, 2026.
Dr. Bigora retains all previously granted equity awards and remains eligible for prior bonus compensation.
Transition is part of her planned path toward retirement, as stated by the company.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Sian Bigora

Chief Development and Regulatory Officer

PCSA · Processa Pharmaceuticals, Inc.

Effective: 2026-05-01
Filed: April 30, 2026, 7:59 PM ET

On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sian Bigora changed role as Chief Development and Regulatory Officer at Processa Pharmaceuticals, Inc..

Action: transitioned from full-time executive officer to part-time employee
Role: Chief Development and Regulatory Officer

Exact text from the filing

On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.

View on SEC.gov

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-020728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.